KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Debt to Equity (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Debt to Equity for 6 consecutive years, with $0.02 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Debt to Equity fell 37.81% year-over-year to $0.02, compared with a TTM value of $0.02 through Dec 2025, down 37.81%, and an annual FY2025 reading of $0.02, down 37.81% over the prior year.
  • Debt to Equity was $0.02 for Q4 2025 at Recursion Pharmaceuticals, down from $0.02 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.05 in Q3 2024 and bottomed at -$0.04 in Q1 2021.
  • Average Debt to Equity over 5 years is $0.01, with a median of $0.0 recorded in 2023.
  • The sharpest move saw Debt to Equity plummeted 90.87% in 2022, then surged 2055.72% in 2024.
  • Year by year, Debt to Equity stood at $0.0 in 2021, then fell by 5.37% to $0.0 in 2022, then surged by 123.34% to $0.0 in 2023, then skyrocketed by 976.39% to $0.03 in 2024, then tumbled by 37.81% to $0.02 in 2025.
  • Business Quant data shows Debt to Equity for RXRX at $0.02 in Q4 2025, $0.02 in Q3 2025, and $0.02 in Q2 2025.